Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Overview

To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper [first toleration of solid food] and lower [first bowel movement] gastrointestinal recovery) compared to placebo.

Full Title of Study: “A Randomized, Double-blind, Single-Center Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery After Surgery ERAS Protocol”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: January 1, 2021

Detailed Description

A prospective, randomized, single-center double blind trial of Alvimopan versus placebo for improving patient outcomes and cost during radical cystectomy and urinary diversion will be performed. A randomized trial is necessary to control for all the known and unknown confounders associated with instituting this novel intervention into a surgical procedure. We will recruit 136 subjects (63 patients in each arm of the study per sample size calculation below, plus additional 10 subjects to account for drop outs). A control group will be administered a placebo in order to directly compare if the Alvimopan intervention is effective.

Interventions

  • Drug: Alvimopan
    • To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
  • Drug: Placebo
    • To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.

Arms, Groups and Cohorts

  • Active Comparator: Oral Alvimopan
    • Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
  • Placebo Comparator: Matching Placebo
    • Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).

Clinical Trial Outcome Measures

Primary Measures

  • Time to Return of Bowel Function
    • Time Frame: From Day of surgery (Day 0) to Day 30
    • To achieve quicker time to return bowel function measured by a composite endpoint of both upper GI recovery (GI-2 recovery = [first toleration of solid food] and lower (first bowel movement) gastrointestinal recovery, taking Alvimopan during radical cystectomy, compared to placebo.

Secondary Measures

  • Post-operative Length of Stay
    • Time Frame: Day of surgery (Day 0) to Day of Discharge (Up to Day 30)
    • Post operative LOS was determined by the difference between the date of hospital discharge and the date of surgery; that is the postoperative LOS for a participant was calculated as follows:(date of discharge)-(date of surgery).
  • Post-operative Morbidity
    • Time Frame: During hospitalization up to 7 days after surgery
    • POM defined as need for nasogastric (NG) tube insertion, hospital stay prolonged because of post-operative ileus (POI) beyond 10 days, or readmission to hospital for POI within 7 days after discharge.
  • 30 Day Complications
    • Time Frame: Day of surgery (Day 0) to Day 30
    • Any Clavien Grade II-V complication.
  • Readmission to Hospital
    • Time Frame: Day of Discharge (Up to Day 30)
    • Any readmission to hospital for > 24 hours after discharge.
  • Open vs Robotic Radical Cystectomy
    • Time Frame: Day of Surgery (Day 0)
    • To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in decreased time to GI2 recovery
  • Cost Analysis
    • Time Frame: Day of surgery (Day 0) to Day 30
    • To evaluate costs of surgery and post-operative care between alvimopan and placebo in patients having a radical cystectomy and urinary diversion.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients undergoing radical cystectomy and urinary diversion via open or robotic approach. – Man or woman between the ages of 18 and 85. – American Society of Anesthesiologists (ASA) Physical Status Score of class 1-4 – Ileal conduit or ileal neobladder urinary diversion – Able to understand the study procedures, agreed to participate in the study program, and voluntarily provided informed consent Exclusion criteria:

  • Patients who met any of the following criteria were excluded from participating in the study: – Scheduled for a partial cystectomy – Previous total colectomy, gastrectomy, or gastric bypass, or functional colostomy or ileostomy – More than three doses of opioids (oral or parenteral) within 7 days before the day of surgery – Chemotherapy for bladder cancer within 1 month of scheduled surgery; prior neoadjuvant chemotherapy allowed. – Pregnant (identified by a positive serum pregnancy test administered after the initial screening process and before the commencement of study activities) or lactating, or not postmenopausal (no menses for at least 1 year) and of childbearing potential and not using an accepted method of birth control (i.e, surgical sterilization; intrauterine contraceptive device; oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam; or abstinence) (Participants will be asked to use birth control for the entire study and for at least 2 weeks after the last dose of study drug.) – Participated in another investigational drug or medical device study within 30 days of surgery or planning to be enrolled in another investigational drug or medical device study or any study in which active patient participation was required outside normal hospital data collection during the course of this study – Clinically significant laboratory abnormalities at screening that would have resulted in the cancellation of surgery – Using illicit drugs or abusing alcohol – History of previous surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might have confounded the study results or might have posed additional risk in administering the study procedures – Patients with severe dementia (as determined from medical records and history. Severe dementia will be defined as dementia that impacts daily functioning.) – Patients with severe hepatic impairment. – Patients with end-stage renal disease. – Patients with heart failure. . – Patients with complete gastrointestinal obstruction.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Brigham and Women’s Hospital
  • Collaborator
    • Merck Sharp & Dohme Corp.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mark Preston, Urological Surgeon – Brigham and Women’s Hospital
  • Overall Official(s)
    • Mark A Preston, MD, Principal Investigator, Brigham and Women’s Hospital
  • Overall Contact(s)
    • Martin Barylak, 6175258274, mbarylak@bwh.harvard.edu

References

Vora AA, Harbin A, Rayson R, Christiansen K, Ghasemian R, Hwang J, Verghese M. Alvimopan provides rapid gastrointestinal recovery without nasogastric tube decompression after radical cystectomy and urinary diversion. Can J Urol. 2012 Jun;19(3):6293-8.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.